Quarterly snapshots from biopharma companies with marketed products, including: Acceleron, Alimera, Coherus, Collegium, Radius, Rigel, Sage.

Quarterly snapshots from biopharma companies with marketed products, including: Amarin, Jazz, United Therapeutics, Vanda.

Quarterly snapshots from biopharma companies with marketed products, including: Intercept, Insmed, Theratechnologies.

Ultragenyx Pharmaceutical Inc.’s top-line win in January with DTX-301 gene therapy in ornithine transcarbamylase (OTC) deficiency seemed to presage even better things to come later this year, and analysts more recently hailed fourth-quarter earnings that showed satisfying progress with Crysvita (burosumab).

Quarterly snapshots from biopharma companies with marketed products, including: Karyopharm.

Quarterly snapshots from biopharma companies with marketed products, including: Acorda, Alkermes, Incyte, Ironwood.

Quarterly snapshots from biopharma companies with marketed products, including: Seattle Genetics, Takeda Pharmaceutical.

Quarterly snapshots from biopharma companies with marketed products, including: Seattle Genetics.

Quarterly snapshots from biopharma companies with marketed products, including: Alnylam, Regeneron.

Modest revenue growth and a 2020 outlook that left analysts uninspired about its near-term prospects pushed Gilead Sciences Inc. shares (NASDAQ:GILD) down about 2% to close Feb. 5 at $65.87, despite growing sales of its HIV medicine, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide), and what CEO Daniel O'Day called "a sense of urgency" around further business development.